WinstonWınston
InfuSystem Holdings logo

InfuSystem Holdings

INFU
62
Medical - Instruments & Supplies · Healthcare
Price
$8.92
-0.32 (-3.46%)
Market Cap
$180.0M
Exchange
New York Stock Exchange American
Winston Score
62
Winston is curious
A decent business — some strong pillars, some weaker.

Share count falling — buybacks

4.3% over 4y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 22.0M (2021) → 21.1M (2025)

InfuSystem Holdings is a healthcare company that provides infusion therapy services and equipment across the United States. It rents and manages infusion pumps — devices that deliver medicine, like chemotherapy drugs, directly into a patient's body at a controlled rate. Its main customers are hospitals, oncology clinics, and other healthcare providers who need these pumps without buying and maintaining them outright.

The company makes money primarily by renting infusion pumps and providing related services, including pump management, repair, and logistics support. It operates entirely within the U.S. and generates around $120–130 million in annual revenue. Its competitive position comes from being one of the few scaled, specialized pump rental networks in the country, which makes it difficult for smaller competitors to match its service coverage. The key growth driver is expanding its oncology and pain management pump programs, but the main risk is customer concentration and reimbursement pressure from insurers and Medicare, which could squeeze margins over time.

Winston Score History

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-3.0% YoY

YoY Growth Rate

Revenue declining

EPS Growth

+603.0% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$0/ year

0.0% of revenue

Below sector average (18%)

Research and development spending

Insider Activity

7.3%ownership

Insiders own a meaningful stake in the company

Cash Runway

~7 months

$2M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Short runway — potential dilution ahead through share issuance

Cash watch

InfuSystem Holdings has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
58.4%
Premium pricing power — 58.4% gross margin
Operating Margin
4.7%
Thin — 4.7% operating margin
ROCE
2.0%
Weak — 2.0% return on capital

ROIC between 0% and 5%. They earn a few cents back per dollar invested in the business.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
+3.5%
Slow sales growth (3.5% YoY)
EPS YoY
+164.3%
Earnings growing fast (164.3% YoY)

Earnings growing 25%+ a year. The compounder zone.

EPS Consistency
8/8 quarters
Every recent quarter grew earnings vs last year

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
298%
Turns 298% of profit into real cash
FCF Margin
13.5%
Converts sales into free cash efficiently (13.5%)

FCF margin between 10% and 20%. Every $100 in sales becomes $10 to $20 in real cash.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
0.33
Conservative — low debt load (0.33)
Interest Cover
15.35x
Comfortably covers interest (15.3x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
23.5x
Growth-priced — P/E 23.5

P/E above the market average. People are paying up for expected growth.

P/E vs Forward
+1.7
GROWING
Earnings expected to grow — slightly cheaper on forward P/E

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial